AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10362169 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor
Number of subjects: 255
Study 10362169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early epidural placement
Number of subjects: 255
Study 10362169 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study 7579848 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm (37 degrees C)
Number of subjects: 51
Study 7579848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid (32 degrees C)
Number of subjects: 51
Study 7579848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold (20 degrees C)
Number of subjects: 51
Study 7579848 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 51
Study 2288825 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg p.o.
Number of subjects: 22
Study 2288825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg p.o.
Number of subjects: 22
Study 6250699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg every 12 hours)
Number of subjects: 37
Study 6250699 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (10 mg every 12 hours)
Number of subjects: 37
Study 6250699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone and Prochlorperazine
Number of subjects: 37
Study 6250699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 37
Study 6250699 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 37
Study 31397827 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Children's Hospital of Pittsburgh Pediatric Logistic Organ Dysfunction‐2 score
Number of subjects: 21335
Study 31397827 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Children's Hospital of Pittsburgh Pediatric Risk of Mortality‐IV
Number of subjects: 21335
Study 31397827 — intervention group
Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 21335
Study 28408814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent volume-assured pressure support (IVAPS)
Number of subjects: 14
Study 28408814 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled (spontaneous timed [ST]) non-invasive ventilation
Number of subjects: 14
Study 26487343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF)
Number of subjects: 4747
Study 26487343 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine (FTC)
Number of subjects: 4747
Study 26487343 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 4747
Study 26487343 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 4747
Study 23599623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of normal saline and hydroxyethyl starch (HES) (SH group)
Number of subjects: 120
Study 23599623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of normal saline, hydroxyethyl starch and glutamine (SHG group)
Number of subjects: 120
Study 21566420 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Number of subjects: 0
Study 19289857 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 533
Study 19289857 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 533
Study 19289857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 19289857 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 533
Study 16415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Restasis (0.05% cyclosporine) + Systane
Number of subjects: 61
Study 16415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane
Number of subjects: 61
Study 16415689 — intervention group
Group type: COMPARATOR
Intervention: Restasis (0.05% cyclosporine) + Refresh
Number of subjects: 61
Study 16415689 — intervention group
Group type: COMPARATOR
Intervention: Systane alone
Number of subjects: 61
Study 15470281 — intervention group
Group type: EXPERIMENTAL
Intervention: IUCD users
Number of subjects: 100
Study 15470281 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study 11419611 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Meditation (twice a day for 15 minutes for six weeks)
Number of subjects: 16
Study 11419611 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Meditation
Number of subjects: 16
Study 11419611 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (symptom monitoring for six weeks)
Number of subjects: 16
Study 9257207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min)
Number of subjects: 118
Study 9257207 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal)
Number of subjects: 118
Study 9257207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min) in women
Number of subjects: 118
Study 9257207 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal) in women
Number of subjects: 118
Study 9257207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (50 to 200 micrograms/kg/min) in men
Number of subjects: 118
Study 9257207 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5 to 1.3% end‐tidal) in men
Number of subjects: 118
Study 9257207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for maintenance of anesthesia
Number of subjects: 118
Study 9257207 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane for maintenance of anesthesia
Number of subjects: 118
Study 8275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 8275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 12
Study 8275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 40 mg
Number of subjects: 12
Study 8275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 120 mg
Number of subjects: 12
Study 8275619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 240 mg
Number of subjects: 12
Study 8275619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3435105 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent containing 4% CHG
Number of subjects: 50
Study 3435105 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid detergent containing 2% CHG
Number of subjects: 50
Study 3435105 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam containing 4% CHG
Number of subjects: 50
Study 3435105 — intervention group
Group type: COMPARATOR
Intervention: Nonantiseptic soap (control)
Number of subjects: 50
Study 28956449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide loaded‐nanoliposome
Number of subjects: 20
Study 28956449 — intervention group
Group type: COMPARATOR
Intervention: Marketed dorzolamide HCl eye drop
Number of subjects: 20
Study 27004531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 mcg as a slow intravenous bolus
Number of subjects: 100
Study 27004531 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin 100 mcg as a short-infusion in 100 ml 0.9% sodium chloride
Number of subjects: 100
Study 25339342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet for 4 weeks
Number of subjects: 42
Study 25339342 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 42
Study 23511711 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.0001‐3 mg)
Number of subjects: 12
Study 23511711 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (400 mg q.d.)
Number of subjects: 12
Study 20107296 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) 50 mg/day
Number of subjects: 0
Study 20107296 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) > 50 mg/day
Number of subjects: 0
Study 20107296 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS) 50-100 mg/day
Number of subjects: 0
Study 20107296 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate (DVS)
Number of subjects: 0
Study 18387161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 15
Study 16246442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g) administration
Number of subjects: 21
Study 16246442 — intervention group
Group type: COMPARATOR
Intervention: No ascorbic acid administration (control)
Number of subjects: 21
Study 12687332 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 12
Study 12687332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole (first dose 200 mg)
Number of subjects: 12
Study 12687332 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil and itraconazole combination
Number of subjects: 12
Study 12687332 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 12
Study 12687332 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil alone and in combination with itraconazole
Number of subjects: 12
Study 12687332 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10588314 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg once daily
Number of subjects: 922
Study 10588314 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir 500 mg twice daily
Number of subjects: 922
Study 8678177 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital/crisis respite program
Number of subjects: 197
Study 8678177 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospitalization
Number of subjects: 197
Study 1656713 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI treatment (sorbinil)
Number of subjects: 0
Study 1656713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6356855 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 32
Study 6356855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31857319 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker (AR-V7) guided clinical treatment
Number of subjects: 70
Study 31857319 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard management (no biomarker guidance)
Number of subjects: 70
Study 30240342 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent and data-sharing scenarios (3 different scenarios)
Number of subjects: 5737
Study 27120420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Health Anxiety (CBT-HA)
Number of subjects: 444
Study 27120420 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 444
Study 25417405 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmailong injection
Number of subjects: 102
Study 25417405 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 102
Study 22458917 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS‐06C (75 mg tramadol/650 mg paracetamol)
Number of subjects: 277
Study 22458917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 20492026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Programme (6-week duration)
Number of subjects: 317
Study 20492026 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 317
Study 18628467 — intervention group
Group type: EXPERIMENTAL
Intervention: Poxvirus-based PSA vaccine
Number of subjects: 42
Study 18628467 — intervention group
Group type: COMPARATOR
Intervention: Nilutamide
Number of subjects: 42
Study 18628467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine followed by Nilutamide
Number of subjects: 42
Study 18628467 — intervention group
Group type: COMPARATOR
Intervention: Nilutamide followed by Vaccine
Number of subjects: 42
Study 18628467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine arm (Gleason score <7)
Number of subjects: 42
Study 18628467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine arm (PSA <20 ng/dL)
Number of subjects: 42
Study 18628467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine arm (prior radiation therapy)
Number of subjects: 42
Study 15959537 — intervention group
Group type: EXPERIMENTAL
Intervention: AM(ex) (0600-0800 h; 30 min at 50% VO(2peak))
Number of subjects: 14
Study 15959537 — intervention group
Group type: EXPERIMENTAL
Intervention: PM(ex) (1700-1900 h)
Number of subjects: 14
Study 15959537 — intervention group
Group type: EXPERIMENTAL
Intervention: AM(ex) and PM(ex)
Number of subjects: 14
Study 15959537 — intervention group
Group type: COMPARATOR
Intervention: Control days (not specified)
Number of subjects: 14
Study 11840030 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with added nucleotides
Number of subjects: 267
Study 11840030 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula without added nucleotides
Number of subjects: 267
Study 11840030 — intervention group
Group type: COMPARATOR
Intervention: Human milk/formula
Number of subjects: 267
Study 9709767 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 220
Study 9709767 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 220
Study 8018638 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone
Number of subjects: 32
Study 8018638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8018638 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone and Placebo
Number of subjects: 32
Study 2521997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 25
Study 2521997 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 25
Study 2521997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31530570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype child restraint instructional materials
Number of subjects: 44
Study 31530570 — intervention group
Group type: COMPARATOR
Intervention: Existing instructional materials for the same restraint (Control)
Number of subjects: 44
Study 30320503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Antidiabetic Drugs (OAD)
Number of subjects: 434629
Study 30320503 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 434629
Study 26972358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dressing (Healoderm)
Number of subjects: 34
Study 26972358 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing material
Number of subjects: 34
Study 24716681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase plus heparin
Number of subjects: 1006
Study 24716681 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 1006
Study 22425308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone graft (BPTB)
Number of subjects: 62
Study 22425308 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle hamstring graft (HT-SB)
Number of subjects: 62
Study 22425308 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle hamstring graft (HT-DB)
Number of subjects: 62
Study 22425308 — intervention group
Group type: COMPARATOR
Intervention: All groups (BPTB, HT-SB, HT-DB)
Number of subjects: 62
Study 20574538 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus amodiaquine (AQ)
Number of subjects: 1008
Study 20574538 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus piperaquine (PQ)
Number of subjects: 1008
Study 20574538 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus piperaquine (PQ)
Number of subjects: 1008
Study 20574538 — intervention group
Group type: COMPARATOR
Intervention: Control group (age matched children)
Number of subjects: 1008
Study 18079051 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat PSA test
Number of subjects: 4102
Study 15677608 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline augmentation of antipsychotic medication
Number of subjects: 0
Study 15677608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 13679527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity warfarin (INR 3.1 to 4.0)
Number of subjects: 114
Study 13679527 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity warfarin (INR 2.0 to 3.0)
Number of subjects: 114
Study 13679527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity warfarin
Number of subjects: 114
Study 13679527 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity warfarin
Number of subjects: 114
Study 11423583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 80
Study 11423583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 8994481 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin
Number of subjects: 431
Study 8994481 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin
Number of subjects: 431
Study 8994481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 7957469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow immunoscintigraphy using a 99mTc‐labelled anti‐NCA‐95 monoclonal antibody
Number of subjects: 58
Study 7957469 — intervention group
Group type: COMPARATOR
Intervention: Conventional bone scintigraphy with 99mTc‐methylene‐diphosphonate
Number of subjects: 58
Study 7957469 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow immunoscintigraphy
Number of subjects: 58
Study 2887726 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (18 mg a day)
Number of subjects: 48
Study 2887726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2887726 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (after placebo)
Number of subjects: 48
Study 2887726 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine overall
Number of subjects: 48
Study 2234996 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 0
Study 2234996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (integration of nonretarded children and EMR adolescents)
Number of subjects: 400
Study 4599852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not integrated)
Number of subjects: 400
Study 4599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects in all groups
Number of subjects: 400
Study 4599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Male subjects in all groups
Number of subjects: 400
Study 30922733 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily on days 1–14 of a 21-day cycle, for eight cycles)
Number of subjects: 447
Study 30922733 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 447
Study 30922733 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 447
Study 28554599 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 q1w (7.5, 15, 22.5, and 30mg doses)
Number of subjects: 0
Study 25832034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical TAVR (TA-TAVR)
Number of subjects: 501
Study 25832034 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral TAVR (TF-TAVR)
Number of subjects: 501
Study 22945837 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pectopexy
Number of subjects: 83
Study 22945837 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sacral colpopexy
Number of subjects: 83
Study 21253394 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick test (Biohit Plc, Helsinki, Finland)
Number of subjects: 185
Study 21253394 — intervention group
Group type: COMPARATOR
Intervention: CLO test (Kimberly‐Clark, Utah, USA)
Number of subjects: 185
Study 21253394 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick test
Number of subjects: 185
Study 21253394 — intervention group
Group type: COMPARATOR
Intervention: CLO test
Number of subjects: 185
Study 21253394 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to Quick test
Number of subjects: 185
Study 18854973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic mask
Number of subjects: 34
Study 18854973 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 34
Study 17276529 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 143
Study 17276529 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 143
Study 15554568 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (titrated from 0.5 mg/kg per day in week 1 to 1.0 mg/kg per day in week 3)
Number of subjects: 45
Study 15554568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15554568 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 45
Study 11483834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine (1 or 2 doses)
Number of subjects: 1602
Study 11483834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine
Number of subjects: 1602
Study 9663731 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g b.d.)
Number of subjects: 170
Study 9663731 — intervention group
Group type: COMPARATOR
Intervention: Docusate sodium (100 mg b.d.)
Number of subjects: 170
Study 8164599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 686
Study 8164599 — intervention group
Group type: COMPARATOR
Intervention: Antacid (40 mmol/day)
Number of subjects: 686
Study 3257375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 15 mg/kg administered intravenously shortly before cannulation (Group 2)
Number of subjects: 0
Study 3257375 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole 30 mg/kg administered intravenously during induction of anesthesia (Group 1)
Number of subjects: 0
Study 31748467 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 mg evolocumab every 4 weeks (Q4W)
Number of subjects: 61
Study 31748467 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg evolocumab every 2 weeks (Q2W)
Number of subjects: 61